ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
Comparison of ovarian vein embolization alone with pelvic venous plexus embolization in the treatment of pelvic venous disorders at 12-month follow-up.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pelvic venous disorders: Objective hemodynamic signature from quantitative two-dimensional phase-contrast magnetic resonance imaging.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePercutaneous endovenous embolization has emerged as a treatment of choice for nonobstructive pelvic venous disorders (PeVD) due to its effectiveness, ease of application, and less invasiveness compared with surgical interventions. In this study, we aimed to analyze 12-month outcomes of the pelvic venous plexus embolization (PVPE) approach and the ovarian vein embolization alone (OVEA) approach.
methodsThis retrospective cohort included 72 women with PeVD who underwent percutaneous endovenous embolization between 2022 and 2024. Patients were assigned to OVEA or PVPE. Symptoms such as chronic pelvic pain, dyspareunia, postcoital pain, and dysmenorrhea were assessed using the visual analog scale at baseline and 12 months. Bladder symptoms were recorded as present/absent. Recurrence was defined as reappearance or worsening of symptoms within 12 months postprocedure. The primary outcome was 12-month symptom relief; secondary outcomes were recurrence and complications.
resultsTechnical success rate was 100%. Visual analog scale scores for chronic pelvic pain, dyspareunia, and postcoital pain at the 12th month were significantly lower in the PVPE group compared with OVEA (P = .001, P = .008, and P = .005, respectively). Recurrence was statistically significantly lower in two patients in the PVPE group compared with nine patients in the OVEA group (P = .036). The mean diagnosis time was found to be 34.98 ± 9.03 months.
conclusionsPeVD is a heterogeneous clinical condition in which both venous reflux and venous outflow obstruction may contribute to symptom development. Our study demonstrated that, in patients with nonobstructive PeVD, the PVPE approach may provide better symptomatic relief and reduced recurrence rates. Long-term results of this approach should be supported by further studies to reach a more solid scientific basis for the management of PeVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.